A Phase 3 interventional study of Benralizumab 30 mg and Matched placebo in Nasal Polyposis and Eosinophilic Chronic Rhinosinusitis, sponsored by AstraZeneca. Terminated at 116 sites in 17 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-19.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Nasal Polyps with a site in China — 17 open to participants now, 24 under way, 7 of them phase 3. Nasal Polyps · China.
Among the 46 studies in Nasal Polyps with a site in China, this one is the 4th largest by enrollment of the 43 interventional ones that give a count, is the only one that started in 2019, is one of 14 in phase 3, and was the 7th registered.
236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.
Browse Nasal Polyps studies →17 of the 46 studies in Nasal Polyps with a site in China are open now. Recruiting first, the newest first:
AstraZeneca · Sites in China
Ages 18+
Bambusa Therapeutics · Sites in China
Ages 18–75 · Healthy volunteers
Tang-Du Hospital · Sites in China
Ages 18–65
Guangdong Hengrui Pharmaceutical Co., Ltd · Sites in China
Ages 18–75
The Affiliated Hospital of Qingdao University · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 16 · Phase 3 15 · Phase 4 4
First in 2010; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 295 is above the median of 60 across 181 interventional studies indexed under Nasal Polyps.
Median enrollment 90 across the 43 interventional studies, 146 across the 3 observational. Of the 17 that completed or were terminated, 6 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 46 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 8 studies filed under Nasal Polyps — fewer than ten, so there is no comparison to draw.
6 of the studies in Nasal Polyps with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07424144Phase 3SanofiAn Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps | 2027-02-17 |
| NCT07107256Phase 3Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps | 2027-03 |
| NCT06338995Phase 3Eli Lilly and CompanyA Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) | 2027-05 |
| NCT07313917Longbio PharmaA Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | 2027-02-28 |
| NCT07755371AkesoA Study to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Rhinosinusitis With Nasal Polyps | 2027-04-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 46 studies in Nasal Polyps with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo-controlled, parallel-group, international, multicenter, Phase 3 study to evaluate the efficacy and safety of repeat dosing of benralizumab 30 mg administered subcutaneously (SC) versus placebo in patients with severe nasal polyposis.
Approximately 250 patients will be randomized to receive benralizumab 30 mg SC or matching placebo. After enrolment, eligible patients will enter a 6-week screening/run in period. Patients who meet eligibility criteria will be randomised 1:1 at Week 0 (Day 0) to receive either placebo or benralizumab 30 mg SC every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48). An end of treatment visit will be conducted at Week 56.All patients who complete the 56-week DB treatment period on investigational product (IP) may be eligible to continue into around one year OLE (Open Label Extension), during which all patients will receive 8 doses of benralizumab 30 mg. Patients in Benra arm during DB period will receive one dummy dose for the second dose during OLE (Open Label Extension). The last study visit will occur at 8 weeks after the last dose of IP (Week 112/FU). Patients who do not enter OLE (Open Label Extension), will have their last study visit at Week 56 (EoDB) for follow-up and without administration of IP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Patients with conditions that makes them non evaluable for the co-primary efficacy endpoint including but not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Benralizumab administered subcutaneously
Biological: Benralizumab 30 mg
Placebo administered subcutaneously
Biological: Matched placebo
Benralizumab is 30 mg/ml solution for injection in accessorized pre-filled syringe, 1 ml fill volume. Benralizumab 30 mg subcutaneously will be injected every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48). For OLE, Benralizumab 30 mg subcutaneously will be injected every 4 weeks for the first 3 doses and every 8 weeks for the rest 5 doses. For the patients on Benralizumab treatment during double blind period, placebo will be dosed at the second dose during OLE.
Matching placebo solution for injection in accessorized pre-filled syringe. 1 ml fill volume. Matching placebo subcutaneously will be injected every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48).
Change From Baseline in Endoscopic Total Nasal Polyp Score (NPS) at Week 56
The total nasal polyp score (NPS) is the sum of the right and left nostril scores (maximum of 8), as evaluated by nasal endoscopy. Higher scores indicate greater symptom severity. The left and right score will be based on a central read with a scale from 0 to 4. Each nasal endoscopy is evaluated by two independent physician reviewers.
Time frame: Baseline to Week 56
Change From Baseline in Mean Nasal Blockage Score (NBS) at Week 56.
The NBS is an item in the NPSD. Patients were asked to rate the severity of their worst nasal blockage over the past 24 hours using the following response options: 0 - none; 1 - mild; 2 - moderate; 3 - severe. Higher scores indicate greater symptom severity. The NBS and the changes from baseline were summarised every two weeks (bi-weekly). Baseline was the average of daily responses from Day -13 to Day 1. Bi-weekly mean were calculated if at least 8 days in each 14-day period had evaluable data; otherwise, the biweekly mean was set to missing.
Time frame: Baseline to week 56
Change From Baseline in Difficulty With Sense of Smell (DSS) Score at Week 56.
The DSS is an item in the NPSD. Patients were asked to rate the severity of their worst difficulty with sense of smell over the past 24 hours using the following response options: 0-none; 1-mild; 2-moderate; 3-severe. Higher scores indicate greater symptom severity. The DSS and the changes from baseline were summarised every two weeks (bi-weekly). Baseline was the average of daily responses from Day -13 to Day 1. Bi-weekly mean of DSS was calculated if at least 8 days in each 14-day period have evaluable data; otherwise the bi-weekly mean was set to missing.
Time frame: Baseline to Week 56
Sinus Opacification by CT Scan at Week 56.
Change from baseline in Lund- Mackay score (LMS). The Lund-Mackay score scoring system is used to provide a quantitative assessment of nasal sinuses on sinus CT scans. Based on the sinus CT images, the five sinuses (maxillary, anterior ethmoid, posterior ethmoid, sphenoid and frontal) on each site are score by central radiologist as follows: (0-Normal; 1-Partial Opacification; 2-Total Opacification). The osteomeatal complex is scored for right and left sides (0 - Not occluded; 2- Occluded). The total score ranges from 0 to 24 (higher scores indicate poorer outcomes).
Time frame: Baseline to Week 56
Disease Specific Health-related Quality of Life (HRQoL): Change From Baseline in SinoNasal Outcome Test (SNOT-22) Score at Week 56.
SinoNasal Outcome Test 22 scores are participant-reported and assess physical problems, functional limitations and emotional consequences of SinoNasal conditions. Patient-reported symptom severity and symptom impact over the past 2 weeks are captured via a 6-point scale (0-No Problem to 5-Problem as bad as it can be). The total score is the sum of item scores and has a range from 0 to 110 (higher scores indicate poorer outcomes).
Time frame: Baseline to Week 56
Time to First Nasal Polyp Surgery
Time to the first surgery for CRSwNP= Start date of the first surgery for CRSwNP - date of randomisation + 1
Time frame: Baseline to Week 56
Time to First SCS Course for CRSwNP
Time to the first SCS use for CRSwNP = Start date of the first SCS use for CRSwNP - date of randomisation + 1
Time frame: Baseline to Week 56
Time to First NP Surgery and/or SCS Use for CRSwNP
Time to first surgery and/or SCS use for CRSwNP = earlier date of (start date of first surgery for CRSwNP, start date of first SCS use for CRSwNP) - date of randomisation + 1
Time frame: Baseline to Week 56
Change From Baseline in Bi-weekly Mean Nasal Polyps Symptom Diary Total Symptom Score at Week 56.
The participant completed the nasal polyposis symptom diary each morning throughout the study. The participant was asked to consider their experience with nasal polyposis/nasal polyps over the past 24 hours when responding to each question. Participants were asked to report their experience with nasal polyposis symptoms (nasal blockage, nasal congestion, runny nose, postnasal drip (mucus drainage down the throat), headache, facial pain, facial pressure, difficulty with sense of smell). Participants reported the severity of each symptom and symptom impact at its worst using a 4-point verbal rating scale (0-None to 3-Severe). A total symptom score (range from 0 to 24) was calculated by taking the sum of the 8 equally weighted symptom items. Higher scores indicate greater symptom severity.
Time frame: Baseline to Week 56
Percentage of Participants With Surgery and/or Use SCS for CRSwNP
Nasal polyps surgery is defined as any procedure involving instruments resulting in incision and removal of tissue (e.g. polypectomy, endoscopic sinus surgery). An SCS course can be considered as a new course if the start date is preceded by at least 7 days after the end date of the last SCS course for CRSwNP (i.e. start date of the new course - end date of the last course \> 7)
Time frame: Baseline to Week 56
Percentage of Participants With Surgery for CRSwNP
Nasal polyps surgery is defined as any procedure involving instruments resulting in incision and removal of tissue (e.g. polypectomy, endoscopic sinus surgery).
Time frame: Baseline to Week 56
Percentage of Participants With SCS Use for CRSwNP
An SCS course can be considered as a new course if the start date is preceded by at least 7 days after the end date of the last SCS course for CRSwNP (i.e. start date of the new course - end date of the last course \> 7)
Time frame: Baseline to Week 56
A total of 723 participants were screened between 15NOV2019 and 01JUN2023. Of those, 295 were randomized to either the treatment (147 participants) or placebo (148 participants) arms of the double-blind treatment period. Eight participants were excluded due to Japan GCP breach. Therefore, 144 participants started in the treatment arm and 143 in the placebo arm, for a total of 287 participants.
| Milestone | Double Blind Benralizumab | Double Blind Placebo |
|---|---|---|
| Started | 144 | 143 |
| Completed | 129 | 130 |
| Not completed | 15 | 13 |
| Withdrew: Ip discontinuation | 1 | 1 |
| Withdrew: Withdrawal by subject | 9 | 6 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Physician decision | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Site closure | 2 | 0 |
| Withdrew: Patient did not meet randomization criteria | 0 | 1 |
| Milestone | Double Blind Benralizumab | Double Blind Placebo |
|---|---|---|
| Started | 122 | 125 |
| Completed | 80 | 86 |
| Not completed | 42 | 39 |
| Withdrew: Study terminated by sponsor | 19 | 26 |
| Withdrew: Withdrawal by subject | 18 | 6 |
| Withdrew: Physician decision | 3 | 2 |
| Withdrew: Adverse event | 1 | 3 |
| Withdrew: Patient withdrew due to failure of treatment | 1 | 2 |
The total nasal polyp score (NPS) is the sum of the right and left nostril scores (maximum of 8), as evaluated by nasal endoscopy. Higher scores indicate greater symptom severity. The left and right score will be based on a central read with a scale from 0 to 4. Each nasal endoscopy is evaluated by two independent physician reviewers.
| Score | Double Blind Benralizumab | Double Blind Placebo |
|---|---|---|
| Change From Baseline in Endoscopic Total Nasal Polyp Score (NPS) at Week 56 | -0.3 ± 1.6 | -0.1 ± 1.3 |
The NBS is an item in the NPSD. Patients were asked to rate the severity of their worst nasal blockage over the past 24 hours using the following response options: 0 - none; 1 - mild; 2 - moderate; 3 - severe. Higher scores indicate greater symptom severity. The NBS and the changes from baseline were summarised every two weeks (bi-weekly). Baseline was the average of daily responses from Day -13 to Day 1. Bi-weekly mean were calculated if at least 8 days in each 14-day period had evaluable data; otherwise, the biweekly mean was set to missing.
| Score | Double Blind Benralizumab | Double Blind Placebo |
|---|---|---|
| Change From Baseline in Mean Nasal Blockage Score (NBS) at Week 56. | -0.64 ± 0.98 | -0.45 ± 0.90 |
The DSS is an item in the NPSD. Patients were asked to rate the severity of their worst difficulty with sense of smell over the past 24 hours using the following response options: 0-none; 1-mild; 2-moderate; 3-severe. Higher scores indicate greater symptom severity. The DSS and the changes from baseline were summarised every two weeks (bi-weekly). Baseline was the average of daily responses from Day -13 to Day 1. Bi-weekly mean of DSS was calculated if at least 8 days in each 14-day period have evaluable data; otherwise the bi-weekly mean was set to missing.
| Score | Double Blind Benralizumab | Double Blind Placebo |
|---|---|---|
| Change From Baseline in Difficulty With Sense of Smell (DSS) Score at Week 56. | -0.26 ± 0.78 | -0.05 ± 0.56 |
Change from baseline in Lund- Mackay score (LMS). The Lund-Mackay score scoring system is used to provide a quantitative assessment of nasal sinuses on sinus CT scans. Based on the sinus CT images, the five sinuses (maxillary, anterior ethmoid, posterior ethmoid, sphenoid and frontal) on each site are score by central radiologist as follows: (0-Normal; 1-Partial Opacification; 2-Total Opacification). The osteomeatal complex is scored for right and left sides (0 - Not occluded; 2- Occluded). The total score ranges from 0 to 24 (higher scores indicate poorer outcomes).
| Score | Double Blind Benralizumab | Double Blind Placebo |
|---|---|---|
| Sinus Opacification by CT Scan at Week 56. | -1.3 ± 3.4 | -0.7 ± 3.5 |
SinoNasal Outcome Test 22 scores are participant-reported and assess physical problems, functional limitations and emotional consequences of SinoNasal conditions. Patient-reported symptom severity and symptom impact over the past 2 weeks are captured via a 6-point scale (0-No Problem to 5-Problem as bad as it can be). The total score is the sum of item scores and has a range from 0 to 110 (higher scores indicate poorer outcomes).
| Score | Double Blind Benralizumab | Double Blind Placebo |
|---|---|---|
| Disease Specific Health-related Quality of Life (HRQoL): Change From Baseline in SinoNasal Outcome Test (SNOT-22) Score at Week 56. | -18.0 ± 29.6 | -15.2 ± 26.6 |
Time to the first surgery for CRSwNP= Start date of the first surgery for CRSwNP - date of randomisation + 1
| Months | Double Blind Benralizumab | Double Blind Placebo |
|---|---|---|
| Time to First Nasal Polyp Surgery | 6.31 (3.3 to 10.5) | 7.79 (4.4 to 12.4) |
Time to the first SCS use for CRSwNP = Start date of the first SCS use for CRSwNP - date of randomisation + 1
| Months | Double Blind Benralizumab | Double Blind Placebo |
|---|---|---|
| Time to First SCS Course for CRSwNP | 5.62 (0.1 to 13.0) | 6.37 (0.1 to 11.4) |
Time to first surgery and/or SCS use for CRSwNP = earlier date of (start date of first surgery for CRSwNP, start date of first SCS use for CRSwNP) - date of randomisation + 1
| Months | Double Blind Benralizumab | Double Blind Placebo |
|---|---|---|
| Time to First NP Surgery and/or SCS Use for CRSwNP | 5.70 (0.1 to 13.0) | 6.37 (0.1 to 12.4) |
The participant completed the nasal polyposis symptom diary each morning throughout the study. The participant was asked to consider their experience with nasal polyposis/nasal polyps over the past 24 hours when responding to each question. Participants were asked to report their experience with nasal polyposis symptoms (nasal blockage, nasal congestion, runny nose, postnasal drip (mucus drainage down the throat), headache, facial pain, facial pressure, difficulty with sense of smell). Participants reported the severity of each symptom and symptom impact at its worst using a 4-point verbal rating scale (0-None to 3-Severe). A total symptom score (range from 0 to 24) was calculated by taking the sum of the 8 equally weighted symptom items. Higher scores indicate greater symptom severity.
| Score | Double Blind Benralizumab | Double Blind Placebo |
|---|---|---|
| Change From Baseline in Bi-weekly Mean Nasal Polyps Symptom Diary Total Symptom Score at Week 56. | -3.19 ± 5.78 | -2.32 ± 5.83 |
Nasal polyps surgery is defined as any procedure involving instruments resulting in incision and removal of tissue (e.g. polypectomy, endoscopic sinus surgery). An SCS course can be considered as a new course if the start date is preceded by at least 7 days after the end date of the last SCS course for CRSwNP (i.e. start date of the new course - end date of the last course \> 7)
| Participants | Double Blind Benralizumab | Double Blind Placebo |
|---|---|---|
| Percentage of Participants With Surgery and/or Use SCS for CRSwNP | 26 | 30 |
Nasal polyps surgery is defined as any procedure involving instruments resulting in incision and removal of tissue (e.g. polypectomy, endoscopic sinus surgery).
| Participants | Double Blind Benralizumab | Double Blind Placebo |
|---|---|---|
| Percentage of Participants With Surgery for CRSwNP | 8 | 10 |
An SCS course can be considered as a new course if the start date is preceded by at least 7 days after the end date of the last SCS course for CRSwNP (i.e. start date of the new course - end date of the last course \> 7)
| Participants | Double Blind Benralizumab | Double Blind Placebo |
|---|---|---|
| Percentage of Participants With SCS Use for CRSwNP | 21 | 22 |
Collected over On study AEs were collected from the first dose to the last date in study, up to 112 weeks.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Double Blind Benralizumab | 0/144 (0%) | 12/144 (8.3%) | 78/144 (54.2%) |
| Double Blind Placebo | 0/143 (0%) | 12/143 (8.4%) | 59/143 (41.3%) |
| Double Blind Benralizumab First, Then Open Label Benralizumab | 0/122 (0%) | 6/122 (4.9%) | 37/122 (30.3%) |
| Double Blind Placebo First, Then Open Label Benralizumab | 0/125 (0%) | 9/125 (7.2%) | 33/125 (26.4%) |
| Event | Double Blind Benralizumab | Double Blind Placebo | Double Blind Benralizumab First, Then Open Label Benralizumab | Double Blind Placebo First, Then Open Label Benralizumab |
|---|---|---|---|---|
| COVID-19 pneumoniaInfections and infestations | 0/144 | 0/143 | 2/122 | 1/125 |
| PneumoniaInfections and infestations | 0/144 | 2/143 | 0/122 | 1/125 |
| InfluenzaInfections and infestations | 0/144 | 0/143 | 1/122 | 0/125 |
| Lower respiratory tract infectionInfections and infestations | 0/144 | 1/143 | 1/122 | 1/125 |
| Meniscus injuryInjury, poisoning and procedural complications | 0/144 | 0/143 | 1/122 | 0/125 |
| Invasive breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/144 | 0/143 | 1/122 | 0/125 |
| Chronic rhinosinusitis with nasal polypsRespiratory, thoracic and mediastinal disorders | 0/144 | 0/143 | 1/122 | 1/125 |
| Infective exacerbation of asthmaInfections and infestations | 0/144 | 0/143 | 0/122 | 1/125 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/144 | 0/143 | 0/122 | 1/125 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/144 | 0/143 | 0/122 | 1/125 |
| Event | Double Blind Benralizumab | Double Blind Placebo | Double Blind Benralizumab First, Then Open Label Benralizumab | Double Blind Placebo First, Then Open Label Benralizumab |
|---|---|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 16/144 | 22/143 | 7/122 | 8/125 |
| COVID-19Infections and infestations | 22/144 | 16/143 | 9/122 | 7/125 |
| Upper respiratory tract infectionInfections and infestations | 13/144 | 14/143 | 9/122 | 4/125 |
| NasopharyngitisInfections and infestations | 11/144 | 9/143 | 9/122 | 8/125 |
| HeadacheNervous system disorders | 11/144 | 7/143 | 1/122 | 4/125 |
| Back painMusculoskeletal and connective tissue disorders | 7/144 | 1/143 | 1/122 | 2/125 |
| Influenza like illnessGeneral disorders | 7/144 | 4/143 | 2/122 | 0/125 |
| PyrexiaGeneral disorders | 7/144 | 3/143 | 1/122 | 4/125 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/144 | 6/143 | 2/122 | 3/125 |
| Chronic gastritisGastrointestinal disorders | 6/144 | 1/143 | 0/122 | 2/125 |
All participants who were randomized and received any IP were included in the full analysis set.
| Age, Categorical(Participants) | Double Blind Benralizumab | Double Blind Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 128 | 126 | 254 |
| >=65 years | 16 | 17 | 33 |
| Age, Continuous(Years) | Double Blind Benralizumab | Double Blind Placebo | Total |
|---|---|---|---|
| Mean | 49.5 ± 12.7 | 49.8 ± 12.7 | 49.6 ± 12.7 |
| Sex: Female, Male(Participants) | Double Blind Benralizumab | Double Blind Placebo | Total |
|---|---|---|---|
| Female | 61 | 54 | 115 |
| Male | 83 | 89 | 172 |
| Race/Ethnicity, Customized(Participants) | Double Blind Benralizumab | Double Blind Placebo | Total |
|---|---|---|---|
| White | 77 | 73 | 150 |
| Black or African American | 0 | 2 | 2 |
| Asian | 66 | 66 | 132 |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Other | 1 | 2 | 3 |
Showing the first 100 of 116 sites across 17 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Nov 2019 to primary completion in Aug 2024, 56 months.
Results were first posted in Feb 2026, 1 year 6 months after primary completion. A results delay was requested in Aug 2025.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Benralizumab